4.3 Article

The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

Journal

BMC GASTROENTEROLOGY
Volume 20, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12876-020-1164-0

Keywords

Ulcerative colitis; Quality of life; Work impairment; Activity impairment; Patient-reported outcomes

Funding

  1. Pfizer Inc.

Ask authors/readers for more resources

Background Patients with ulcerative colitis (UC) experience periods of recurring and episodic clinical signs and symptoms. This study sought to establish the association between disease activity and health-related quality of life (HRQoL) and other patient-reported outcomes. Methods United States (US) and European Union 5 ([EU5]; i.e., France, Germany, Italy, Spain, and the United Kingdom) data from the 2015 and 2017 Adelphi Inflammatory Bowel Disease-Specific Programme (IBD-DSP) were used. The IBD-DSP is a database of retrospective patient chart information integrated with patient survey data (EuroQoL-5 Dimensions [EQ-5D], Short Quality of Life in Inflammatory Bowel Disease Questionnaire [SIBDQ], and Work Productivity and Activity Impairment-Ulcerative Colitis [WPAI-UC] questionnaire). Using available chart information, physicians classified their moderate-to-severe patients into one of the following categories: remission with a Mayo endoscopic score = 0 (deep remission), remission without a Mayo endoscopic score = 0 (remission), or active disease. Differences among disease activity categories with respect to patient-reported outcomes were analyzed using generalized linear models, controlling for confounding variables. Results N = 289 and N = 1037 patient charts with linked surveys were included from the US and EU5, respectively. The disease activity distribution was as follows: active disease = 40.1% (US) and 33.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13.3%. Patients with active disease reported significantly lower levels of EQ-5D health state utilities (adjusted mean [AdjM] = 0.87 [US] and 0.78 [EU5]) compared with remission (AdjM = 0.92 and 0.91) and deep remission (AdjM = 0.93 and 0.91) (all P < 0.05 compared with active disease within each region). Similar findings were observed with the scores from the SIBDQ and the WPAI-UC. No significant differences were observed between remission categories. Conclusions Among patients with moderate-to-severe UC in the US and EU5, active disease was associated with significant impairments in HRQoL, work and leisure activities. These results reinforce the importance, to both the patient and society, of achieving some level of remission to restore generic and disease-related HRQoL and one's ability to work productively.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study

Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Raffaele Colucci, Antonio Cuomo, Nicola Della Valle, Antonio Ferronato, Giacomo Forti, Federica Gaiani, GianMarco Giorgetti, Maria Giovanna Graziani, Katia Lofano, Roberto Lorenzetti, Tiziana Larussa, Antonio Penna, Roberta Pica, Giuseppe Pranzo, Stefano Rodino', Antonella Scarcelli, Costantino Zampaletta, Gabrio Bassotti, Alessia Immacolata Cazzato, Stefania Chiri, Valeria Clemente, Andrea Cocco, Gianluigi de' Angelis, Laura Donnarumma, Roberto Faggiani, Camilla Graziosi, Marco Le Grazie, Francesco Luzza, Costantino Meucci, Rita Monterubbianesi, Cristiano Pagnini, Patrizia Perazzo, Marcello Picchio, Rodolfo Sacco, Ladislava Sebkova, Mariaelena Serio, Daniele Napolitano, Daniela Pugliese, Franco Scaldaferri, Elisa Schiavoni, Laura Turchini, Alessandro Armuzzi, Walter Elisei, Giovanni Maconi, Alfredo Papa

Summary: There is no significant difference in the efficacy and safety of different ADA biosimilars in the treatment of inflammatory bowel disease.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program

Edward V. Loftus, Daniel C. Baumgart, Krisztina Gecse, Jami A. Kinnucan, Susan B. Connelly, Leonardo Salese, Chinyu Su, Kenneth K. Kwok, John C. Woolcott, Alessandro Armuzzi

Summary: CDIs in patients with UC receiving tofacitinib were infrequent, with mild-moderate severity, and most cases resolved with treatment.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame

Cristina Bezzio, Gionata Fiorino, Davide G. Ribaldone, Alessandro Armuzzi, Simone Saibeni

Summary: This study investigated the impact of severe acute respiratory syndrome coronavirus 2 infection on inflammatory bowel disease course and found that therapy discontinuation is a risk factor for disease flare.

INFLAMMATORY BOWEL DISEASES (2023)

Editorial Material Gastroenterology & Hepatology

The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease

Konstantinos H. Katsanos, Fotios S. Fousekis, Alessandro Armuzzi

DIGESTIVE AND LIVER DISEASE (2023)

Article Gastroenterology & Hepatology

Proteomic Analysis Identifies Three Reliable Biomarkers of Intestinal Inflammation in the Stools of Patients With Inflammatory Bowel Disease

Roberta Vitali, Francesca Palone, Alessandro Armuzzi, Valerio Fulci, Anna Negroni, Claudia Carissimi, Salvatore Cucchiara, Laura Stronati

Summary: This study identified three novel faecal biomarkers of gut inflammation using proteomic analysis in patients with inflammatory bowel disease. These biomarkers have good specificity and sensitivity for identifying the disease and significantly correlate with disease severity.

JOURNAL OF CROHNS & COLITIS (2023)

Correction Gastroenterology & Hepatology

Simplified Histologic Mucosal Healing Scheme (SHMHS) for inflammatory bowel disease: a nationwide multicenter study of performance and applicability (vol 26, pg 713, 2022)

A. Caputo, P. Parente, M. Cadei, M. Fassan, A. Rispo, G. Leoncini, G. Bassotti, R. Del Sordo, C. Metelli, M. Daperno, A. Armuzzi, V. Villanacci

TECHNIQUES IN COLOPROCTOLOGY (2023)

Editorial Material Gastroenterology & Hepatology

Sarcopenia: A new route on the map for risk stratification in inflammatory bowel disease

Olga Maria Nardone, Alessandro Armuzzi

DIGESTIVE AND LIVER DISEASE (2023)

Article Nutrition & Dietetics

Pomegranate Extract Affects Gut Biofilm Forming Bacteria and Promotes Intestinal Mucosal Healing Regulating the Crosstalk between Epithelial Cells and Intestinal Fibroblasts

Giulia Rizzo, Samuel Elias Pineda Chavez, Elisa Vandenkoornhuyse, Cindy Lorena Cardenas Rincon, Valeria Cento, Valentina Garlatti, Marek Wozny, Giusy Sammarco, Alessia Di Claudio, Lisa Meanti, Sudharshan Elangovan, Andrea Romano, Giulia Roda, Laura Loy, Arianna Dal Buono, Roberto Gabbiadini, Sara Lovisa, Roberto Rusconi, Alessandro Repici, Alessandro Armuzzi, Stefania Vetrano

Summary: This study found that pomegranate extract has beneficial effects in promoting the recovery phase of colitis and the complete restoration of the intestinal barrier. It also affects pathogen biofilm formation and promotes mucosal regeneration through the regulation of the crosstalk between epithelial and stromal cells.

NUTRIENTS (2023)

Review Medicine, General & Internal

Fibro-Stenosing Crohn's Disease: What Is New and What Is Next?

Virginia Solitano, Arianna Dal Buono, Roberto Gabbiadini, Marek Wozny, Alessandro Repici, Antonino Spinelli, Stefania Vetrano, Alessandro Armuzzi

Summary: Fibro-stenosing Crohn's disease (CD) is a common disease presentation that leads to impaired quality of life and often requires endoscopic treatments or surgery. Currently, there are no existing imaging techniques that can accurately quantify the amount of fibrosis within a stricture, and managing patients is challenging, requiring a multidisciplinary team.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Medicine, General & Internal

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study

Ahmad Albshesh, Lian Bannon, Tali Sharar Fischler, Marie Truyens, Stephan R. R. Vavricka, Katja Tepes, Daniela Pugliese, Edoardo V. V. Savarino, Eran Zittan, David Drobne, Xavier Roblin, Ariella Bar-Gil Shitrit, Alessandro Armuzzi, Triana Lobaton, Nitsan Maharshak, Henit Yanai, Shomron Ben-Horin, Uri Kopylov

Summary: The effectiveness of anti-TNF or ustekinumab as a second-line biologic after vedolizumab failure in patients with Crohn's disease was investigated. The results showed that there was no significant difference in the clinical response, remission rate, and discontinuation rate between the use of anti-TNF and ustekinumab as a second-line therapy.

JOURNAL OF CLINICAL MEDICINE (2023)

Editorial Material Gastroenterology & Hepatology

Transperineal Ultrasonography in the Assessment of Rectal Inflammation: Beyond the Monitoring of Ulcerative Colitis

Arianna Dal Buono, Alessandro Armuzzi

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study

Tamas Resal, Peter Bacsur, Csilla Keresztes, Anita Balint, Renata Bor, Anna Fabian, Bernadett Farkas, Kostas Katsanos, George Michalopoylos, Davide Giuseppe Ribaldone, Mohamed Attauabi, Mirabella Zhao, Hadar Amir Barak, Henit Yanai, Cristina Bezzio, Antonio Rispo, Fabiana Castiglione, Ariella Bar-Gil Shitrit, Daniela Pugliese, Alessandro Armuzzi, Edoardo Vincenzo Savarino, Martin Kolar, Milan Lukas, Elena Chashkova, Rafal Filip, Aurore Rozieres, Stephane Nancey, Zeljko Krznaric, Eszter Schafer, Patricia Szamosi, Patricia Sarlos, Matej Franko, David Drobne, Oleg Knyazev, Anna Kagramanova, Jimmy Limdi, Panu Wetwittayakhlang, Peter L. Lakatos, Nitsan Maharshak, Lian Bannon, Tibor Nyari, Zoltan Szepes, Klaudia Farkas, TFB Study Grp, Tamas Molnar

Summary: Background and Aims: This retrospective, international cohort study aimed to evaluate the efficacy and safety of tofacitinib (TFB) in the treatment of moderate-to-severe colitis and acute severe ulcerative colitis (ASUC). The study found that TFB was effective in both indications and resulted in high rates of steroid-free remission in the short and long terms.

INFLAMMATORY BOWEL DISEASES (2023)

Review Biochemistry & Molecular Biology

Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management

Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro, Alessandro Armuzzi

Summary: The introduction of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has significantly changed the therapeutic algorithms for solid tumors. ICIs can lead to immune-related adverse events, with the gastrointestinal tract being commonly affected by varying levels of mucosal inflammation. The pathogenesis of checkpoint inhibitors colitis (CIC) is multifactorial and not fully understood, involving both anti-tumor activity and upregulation of specific inflammatory pathways. Treatment options for CIC, including biological therapy such as anti-TNF alpha, need to be further explored and prompt recognition and treatment are crucial.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Medicine, General & Internal

Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections

Carolina Aliai Micol Cavalli, Roberto Gabbiadini, Arianna Dal Buono, Alessandro Quadarella, Alessandro De Marco, Alessandro Repici, Cristina Bezzio, Edoardo Simonetta, Stefano Aliberti, Alessandro Armuzzi

Summary: Inflammatory bowel diseases (IBDs) are associated with respiratory diseases, even in the absence of symptoms. The same embryological origin and exposure to common antigens and cytokine networks may play a role in respiratory involvement. Early identification and treatment of respiratory manifestations are crucial to prevent lung damage.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Medicine, General & Internal

Mental Illnesses in Inflammatory Bowel Diseases: mens sana in corpore sano

Bianca Bartocci, Arianna Dal Buono, Roberto Gabbiadini, Anita Busacca, Alessandro Quadarella, Alessandro Repici, Emanuela Mencaglia, Linda Gasparini, Alessandro Armuzzi

Summary: Inflammatory bowel diseases (IBD) have been shown to be associated with a high prevalence of psychiatric comorbidities, particularly anxiety and depression. Studies have suggested that the prevalence of mental disorders is higher in IBD patients with active intestinal disease. However, these comorbidities are often under-diagnosed and require more attention in the management of IBD patients.

MEDICINA-LITHUANIA (2023)

No Data Available